Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)

被引：44

作者：

Kashiwagi A. ^{[1
]}

Shiga T. ^{[2
]}

Akiyama N. ^{[2
]}

Kazuta K. ^{[2
]}

Utsuno A. ^{[2
]}

Yoshida S. ^{[2
]}

Ueyama E. ^{[2
]}

机构：

[1] Shiga University of Medical Science, Shiga

[2] Astellas Pharma Inc, 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo

来源：

Diabetology International | 2015年 / 6卷 / 2期

关键词：

Ipragliflozin; Japanese; Pioglitazone; Randomized controlled trial; SGLT2; Type; 2; diabetes;

D O I：

10.1007/s13340-014-0182-y

中图分类号：

学科分类号：

摘要：

Ipragliflozin is a novel oral sodium–glucose cotransporter 2 (SGLT2) inhibitor under development for the treatment of type 2 diabetes. We examined its efficacy and safety as an add-on to pioglitazone in Japanese patients with inadequately controlled diabetes. Japanese type 2 diabetes patients were randomized to 24 weeks of treatment with 50 mg ipragliflozin or placebo in a double-blind manner. At week 24, patients with hemoglobin (Hb)A1c <8.4 % were permitted to continue open-label ipragliflozin in a 28-week extension period. The primary endpoint was the change in HbA1c from baseline to week 24 (with last observation carried forward). Ninety-eight and 54 patients were randomized to ipragliflozin or placebo, respectively, and were prescribed the study drug. The mean HbA1c change from baseline to week 24 was −0.64 % and 0.22 % in the ipragliflozin and placebo groups, respectively, and the adjusted mean difference between the two groups was −0.88 % (P < 0.001). Changes in fasting plasma glucose (FPG) and body weight were significantly greater in the ipragliflozin group (both P < 0.001). Among patients who continued ipragliflozin in the extension period, reductions in HbA1c, FPG, and body weight were maintained until week 52. The incidence of treatment-emergent adverse events was not significantly different between the two groups. The most common event with a higher incidence in the ipragliflozin group than in the placebo group was pollakiuria (12/97 vs. 0/54 patients). Ipragliflozin improved glycemic control, promoted weight reduction, and had a good safety profile as an add-on to pioglitazone in Japanese type 2 diabetes patients. © 2014, The Japan Diabetes Society.

引用

页码：104 / 116

页数：12

共 22 条

[1]

Sabolic I., Vrhovac I., Eror D.B., Gerasimova M., Rose M., Breljak D., Ljubojevic M., Brzica H., Sebastiani A., Thal S.C., Sauvant C., Kipp H., Vallon V., Koepsell H., Expression of Na<sup>+</sup>-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences, Am J Physiol Cell Physiol, 302, pp. C1174-C1188, (2012)

[2]

Bakris G.L., Fonseca V.A., Sharma K., Wright E.M., Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications, Kidney Int, 75, pp. 1272-1277, (2009)

[3]

Nair S., Wilding J.P., Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus, J Clin Endocrinol Metab, 95, pp. 34-42, (2010)

[4]

Kadokura T., Saito M., Utsuno A., Kazuta K., Yoshida S., Kawasaki S., Nagase I., Kageyama S., Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects, Diabetol Int, 2, pp. 172-182, (2011)

[5]

Veltkamp S.A., Kadokura T., Krauwinkel W.J., Smulders R.A., Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects, Clin Drug Investig, 31, pp. 839-851, (2011)

[6]

Schwartz S.L., Akinlade B., Klasen S., Kowalski D., Zhang W., Wilpshaar W., Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus, Diabetes Technol Ther, 13, pp. 1219-1227, (2011)

[7]

Fonseca V.A., Ferrannini E., Wilding J.P., Wilpshaar W., Dhanjal P., Ball G., Klasen S., Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus, J Diabetes Complicat, 27, pp. 268-273, (2013)

[8]

Kashiwagi A., Kazuta K., Yoshida S., Nagase I., Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus, J Diabetes Investig, (2013)

[9]

Wilding J.P., Ferrannini E., Fonseca V.A., Wilpshaar W., Dhanjal P., Houzer A., Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study, Diabetes Obes Metab, 15, pp. 403-409, (2013)

[10]

Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R., Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 35, pp. 1364-1379, (2012)

← 1 2 3 →